198 related articles for article (PubMed ID: 34007175)
1. A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.
Zhang L; Wang M; Zhu Z; Ding C; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Int J Nanomedicine; 2021; 16():3217-3240. PubMed ID: 34007175
[TBL] [Abstract][Full Text] [Related]
2. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics.
Zhang L; Wang M; Zhu Z; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Mol Ther Nucleic Acids; 2021 Dec; 26():732-748. PubMed ID: 34703655
[TBL] [Abstract][Full Text] [Related]
3. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.
Huang YF; Shangguan D; Liu H; Phillips JA; Zhang X; Chen Y; Tan W
Chembiochem; 2009 Mar; 10(5):862-8. PubMed ID: 19253922
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
5. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
6. Modulating Aptamer Specificity with pH-Responsive DNA Bonds.
Li L; Jiang Y; Cui C; Yang Y; Zhang P; Stewart K; Pan X; Li X; Yang L; Qiu L; Tan W
J Am Chem Soc; 2018 Oct; 140(41):13335-13339. PubMed ID: 30212189
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
8. Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging.
Zhong J; Ding J; Deng L; Xiang Y; Liu D; Zhang Y; Chen X; Yang Q
Drug Des Devel Ther; 2021; 15():3985-3996. PubMed ID: 34584404
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.
Sabbih GO; Danquah MK
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445807
[TBL] [Abstract][Full Text] [Related]
10. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
11. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.
Sha YL; Liu Y; Yang JX; Wang YY; Gong BC; Jin Y; Qu TY; Xia FT; Han L; Zhao Q
J Exp Clin Cancer Res; 2022 Oct; 41(1):314. PubMed ID: 36284313
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
14. Selection and characterization of novel DNA aptamer against colorectal carcinoma Caco-2 cells.
Maimaitiyiming Y; Yang C; Wang Y; Hussain L; Naranmandura H
Biotechnol Appl Biochem; 2019 May; 66(3):412-418. PubMed ID: 30746785
[TBL] [Abstract][Full Text] [Related]
15. Selection and identification of a prohibitin 2-binding DNA aptamer for tumor tissue imaging and targeted chemotherapy.
Qiao Y; Shi Y; Ji M; Wang Z; Bai X; Zhang K; Yin K; Zhang Y; Chen X; Zhang Y; Lu J; Zhao J; Liu K; Yuan B
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129002. PubMed ID: 38176501
[TBL] [Abstract][Full Text] [Related]
16. [Efficient screening for 8-oxoguanine DNA glycosylase binding aptamers via capillary electrophoresis].
Han S; Zhao L; Yang G; Qu F
Se Pu; 2021 Jul; 39(7):721-729. PubMed ID: 34227370
[TBL] [Abstract][Full Text] [Related]
17. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
[TBL] [Abstract][Full Text] [Related]
18. Aptamer-drug conjugation for targeted tumor cell therapy.
Donovan MJ; Meng L; Chen T; Zhang Y; Sefah K; Tan W
Methods Mol Biol; 2011; 764():141-52. PubMed ID: 21748638
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
20. Novel Aptamer-Functionalized Nanoparticles Enhances Bone Defect Repair By Improving Stem Cell Recruitment.
Wang M; Wu H; Li Q; Yang Y; Che F; Wang G; Zhang L
Int J Nanomedicine; 2019; 14():8707-8724. PubMed ID: 31806966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
